Compare EOI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
| Metric | EOI | DBVT |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 817.2M | 850.9M |
| IPO Year | 2004 | 2014 |
| Metric | EOI | DBVT |
|---|---|---|
| Price | $19.70 | $12.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.04 |
| AVG Volume (30 Days) | 55.1K | ★ 269.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $18.04 | $8.86 |
| 52 Week High | $21.44 | $26.19 |
| Indicator | EOI | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 40.13 |
| Support Level | $19.39 | N/A |
| Resistance Level | $20.20 | $14.90 |
| Average True Range (ATR) | 0.19 | 0.53 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 32.93 | 27.91 |
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.